Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 6/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4105292 | 1.00 | HDAC4 (0.49) | HDAC4HDAC1HDAC8HDAC3HDAC7 | |
| SCHEMBL4665854 | 0.84 | BACE1 (0.60) | LMNAUSP2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4667485 | 0.81 | USP2 (0.54) | LMNASMN1; SMN2NPSR1HTTUSP2 | |
| SCHEMBL4664257 | 0.81 | CCNT1 (0.64) | USP2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4109389 | 0.79 | EGFR (0.54) | LMNASMN1; SMN2NPSR1USP2CYP1A2 | |
| SCHEMBL4667533 | 0.79 | PIM1 (0.59) | LMNAUSP2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4665763 | 0.79 | CCNT1 (0.59) | USP2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4665690 | 0.78 | POLB (0.56) | LMNASMN1; SMN2HTTUSP2CYP1A2 | |
| SCHEMBL4098855 | 0.78 | MAPT (0.53) | LMNAHTTALDH1A1MEN1KMT2A | |
| SCHEMBL4665747 | 0.77 | MAPT (0.62) | HDAC4HDAC1HDAC8HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | claimed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | claimed |
| US-8084457-B2 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | LEAD DISCOVERY CENTER GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1901747-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | Ingenium Pharmaceuticals AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2006125616-A2 | PYRIMIDINE-BASED CDK INHIBITORS FOR TREATING PAIN | INGENIUM PHARMACEUTICALS AG (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | DAPK1, DUSP4, MARK4 | HDAC4 1050/4885HDAC1 1414/4885HDAC8 1890/4885 |
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | HDAC4 316/4885HDAC1 438/4885HDAC8 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.